I am a
Home I AM A Search Login

Papers of the Week


Papers: 10 Feb 2024 - 16 Feb 2024


2024 Feb 09


Expert Opin Emerg Drugs


38337150

Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention.

Authors

Pellesi L, Ashina M, Martelletti P

Abstract

The pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) has emerged as a key mediator of migraine pathogenesis. PACAP-38 and its receptors are predominantly distributed in arteries, sensory and parasympathetic neurons of the trigeminovascular system. Phase 2 trials have tested human monoclonal antibodies designed to bind and inhibit PACAP-38 and the pituitary adenylate cyclase-activating polypeptide type I (PAC) receptor for migraine prevention.